Crinetics (NASDAQ: CRNX) CFO now holds 79,427 shares after RSU grant

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) reported that Chief Financial & Infra. Ofcr. Tobin Schilke received a grant of 471 restricted stock units (RSUs) of common stock. These RSUs vest 25% annually beginning on September 1, 2027. Following this award, Schilke directly holds 79,427 shares of common stock, including 835 shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary

Net Buyer: 471 shares

Net Buy 1 txn

Insider Schilke Tobin

Role Chief Financial & Infra. Ofcr.

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	471	$0.00	$0.00

Holdings After Transaction: Common Stock — 79,427 shares (Direct)

Footnotes (2)

1. F1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.
2. F2. Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.

Key Figures

Restricted stock units granted: 471 shares Vesting schedule: 25% annually beginning September 1, 2027 Shares held after transaction: 79,427 shares +2 more

5 metrics

Restricted stock units granted 471 shares Grant of RSUs to Chief Financial & Infra. Ofcr. Tobin Schilke

Vesting schedule 25% annually beginning September 1, 2027 Vesting terms for the 471 RSUs

Shares held after transaction 79,427 shares Direct ownership of Tobin Schilke following the RSU grant

ESPP shares included in holdings 835 shares Portion of Schilke’s holdings acquired under Employee Stock Purchase Plan

Transaction price per share $0.0000 Indicates RSU grant was received without cash consideration per share

Key Terms

restricted stock units, vesting, Employee Stock Purchase Plan, Rule 10b5-1

4 terms

restricted stock units financial

"The transaction reported on this line involves the receipt of restricted stock units, which"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Employee Stock Purchase Plan financial

"Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did CRNX report for Tobin Schilke on this Form 4?

The filing reports that Tobin Schilke, Chief Financial & Infra. Ofcr., received a grant of 471 restricted stock units of Crinetics Pharmaceuticals, Inc. common stock, characterized as a grant, award, or other acquisition with no cash price per share listed.

When do Tobin Schilke’s newly granted CRNX restricted stock units begin vesting?

The 471 restricted stock units granted to Tobin Schilke begin vesting with 25% vesting annually starting on September 1, 2027. The remaining RSUs continue to vest in equal annual installments according to this schedule.

How many CRNX shares does Tobin Schilke own after this reported transaction?

After the RSU grant, Tobin Schilke is reported to directly hold 79,427 shares of Crinetics Pharmaceuticals, Inc. common stock. This total includes shares held from various sources, including the company’s Employee Stock Purchase Plan.

How many CRNX shares has Tobin Schilke acquired under the Employee Stock Purchase Plan?

The Form 4 notes that Schilke’s direct holdings include 835 shares acquired under Crinetics Pharmaceuticals, Inc.’s Employee Stock Purchase Plan, which are counted within the reported total of 79,427 shares held following the transaction.

Was Tobin Schilke’s CRNX RSU grant reported as a 10b5-1 trading plan transaction?

No. The filing’s Rule 10b5-1 checkbox is shown as not affirmatively checked, and the footnotes do not state that this RSU grant was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 04:53 PM Accepted by SEC EDGAR 08/24/2026 - 04:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schilke Tobin

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial & Infra. Ofcr.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		A		471	A	$0(1)	79,427(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.

2. Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.

Remarks:

	/s/ Tobin Schilke	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)